Latest News and Press Releases

Preclinical data demonstrates that Shape’s engineered AAV5 variant, SHP-DB1, efficiently targets the NHP brain after intravenous injection and transduces >95% of neurons in the Parkinson's...

Shape Therapeutics to present at the ESGCT 32nd congress on an RNA-targeting gene therapy for Parkinson's Disease and a novel CNS AAV capsid.

Industry-leading RNA editing activity in the CNS of both mice and non-human primates highlights the broad applicability and therapeutic potential of the RNAfix® platform in CNS diseases Preclinical...

SEATTLE, April 28, 2025 (GLOBE NEWSWIRE) -- Shape Therapeutics, a leader in RNA-based gene therapy, today announced the acceptance of multiple abstracts, including two oral presentations, at the...

Shape Therapeutics, a leader in RNA-based gene therapy, today released two preprint manuscripts detailing major technological breakthroughs.

Shape Therapeutics Appoints Healthcare Industry Leaders David Epstein and Todd Simpson to its Board of Directors

RNAfix achieves up to 92% editing in the non-human primate brain after AAV-based gRNA delivery RNAfix achieves >95% editing throughout the mouse brain with sustained durability at least 6 months...

SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, is pleased to announce the...

SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Shape Therapeutics, a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, today announced its upcoming oral presentations...

ShapeTX announces the expansion of its drug discovery partnership with Roche with new target